Although the effect of CFTR modulators on the distribution of F‐actin and endothelial barrier function in primary CF endothelial cells remains to be investigated, evidence is accumulating that the endothelium is potentially a target for CFTR modulator therapy for patients with CFTR mutations for whom specific modulators are available. This evidence concerns the gene CFTR and cystic fibrosis.